Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system

BACKGROUND: Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults. However, real-world data regarding its long-term gastrointestinal safety and tolerability in large sample population are incomplete. We evaluated semag...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yamin, He, Xucheng, Wu, Pan, Liu, Yanxin, Ding, Yufeng, Zhang, Qilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631444/
https://www.ncbi.nlm.nih.gov/pubmed/36339230
http://dx.doi.org/10.3389/fpubh.2022.996179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631444/
https://www.ncbi.nlm.nih.gov/pubmed/36339230
http://dx.doi.org/10.3389/fpubh.2022.996179

Ejemplares similares